Serum PCSK9 levels in infants with deviant birth weight: a biomarker of the lipoprotein metabolism.

Antonios Vlahos,Dimitrios Rallis, Alexandra Lianou,Maria Baltogianni,Niki Dermitzaki,Eleni Maragoudaki,Eleni Papastergiou,Christos Tzallas,Sophia Tsabouri,Alexandros Makis,Ekaterini Siomou,Haralambos Milionis,Vasileios Giapros

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians（2023）

引用 0|浏览9

暂无评分

摘要

PCSK9 levels were significantly associated with total and LDL cholesterol. Moreover, PCSK9 levels were higher in preterm and SGA infants, suggesting that PCSK9 might be a promising biomarker for evaluating infants with increased later cardiovascular risk.Highlights Proprotein Convertase Subtilisin/Kexin-Type 9 (PCSK9) is a promising biomarker for evaluating lipoprotein metabolism; however, evidence in infants is limited. Infants that were born with a deviant birth weight have a unique lipoprotein metabolism profile. Serum PCSK9 levels were significantly associated with total and LDL cholesterol. PCSK9 levels were higher in preterm and small for gestation infants, suggesting that PCSK9 might be a promising biomarker for evaluating infants with increased later cardiovascular risk.

查看译文

关键词

Cardiovascular risk,lipoprotein,metabolism,prematurity,small for gestational age

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要